How do you approach a patient with GCA who has an allergic reaction to a biosimilar of tocilizumab but did well previously on originator tocilizumab?
Would you now avoid all forms of the biologic, biosimilar and original or can you go back to the original formulation assuming you can get insurance to approve?
1 Answer
Mednet Member
Rheumatology · Virginia Mason Franciscan Health Rheumatology Fellowship
Answered on
I wonder whether they may have had a reaction to one of the inactive ingredients in the biosimilar!
I would try to switch back to the originator tocilizumab.
If unsuccessful even with an appeal, could also consider trying the other biosimilar available in the market, although I would prefer to use s...
Join for free or sign in to see the full answer